These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23399042)

  • 1. Preconditions for efficiency and affordability in competitive healthcare markets: are they fulfilled in Belgium, Germany, Israel, the Netherlands and Switzerland?
    van de Ven WP; Beck K; Buchner F; Schokkaert E; Schut FT; Shmueli A; Wasem J
    Health Policy; 2013 Mar; 109(3):226-45. PubMed ID: 23399042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preconditions for efficiency and affordability in competitive healthcare markets: Are they fulfilled in Belgium, Germany, Israel, the Netherlands and Switzerland? Ten years later.
    van de Ven WPMM; Beck K; Buchner F; Schokkaert E; Schut FT; Shmueli A; Wasem J
    Health Policy; 2024 Aug; 146():105099. PubMed ID: 38865863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statutory health insurance competition in Europe: a four-country comparison.
    Thomson S; Busse R; Crivelli L; van de Ven W; Van de Voorde C
    Health Policy; 2013 Mar; 109(3):209-25. PubMed ID: 23395277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk adjustment and risk selection in Europe: 6 years later.
    van de Ven WP; Beck K; Van de Voorde C; Wasem J; Zmora I
    Health Policy; 2007 Oct; 83(2-3):162-79. PubMed ID: 17270311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.
    van de Ven WP; van Vliet RC; van Kleef RC
    Eur J Health Econ; 2017 Mar; 18(2):167-180. PubMed ID: 26837411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consumer mobility in social health insurance markets : a five-country comparison.
    Laske-Aldershof T; Schut E; Beck K; Gress S; Shmueli A; Van de Voorde C
    Appl Health Econ Health Policy; 2004; 3(4):229-41. PubMed ID: 15901197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for regulated competition in the health care system: what can China learn from Russia's experience?
    Xu W; Sheiman I; van de Ven WP; Zhang W
    Health Policy Plan; 2011 May; 26(3):199-209. PubMed ID: 20817697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consumer choice among Mutual Healthcare Purchasers: a feasible option for China?
    Xu W; van de Ven WP
    Soc Sci Med; 2013 Nov; 96():277-84. PubMed ID: 23261255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managed competition in The Netherlands: lessons from five years of health care reform.
    van de Ven W; Rutten F
    Aust Health Rev; 1995; 18(1):9-27. PubMed ID: 10141966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managed care in four managed competition OECD health systems.
    Shmueli A; Stam P; Wasem J; Trottmann M
    Health Policy; 2015 Jul; 119(7):860-73. PubMed ID: 25776034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public healthcare interests require strict competition enforcement.
    Loozen EM
    Health Policy; 2015 Jul; 119(7):882-8. PubMed ID: 25739723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing risk selection incentives in health sector reforms.
    Puig-Junoy J
    Int J Health Plann Manage; 1999; 14(4):287-311. PubMed ID: 11184915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some aspects of the reform of the health care systems in Austria, Germany and Switzerland.
    Theurl E
    Health Care Anal; 1999; 7(4):331-54. PubMed ID: 10787796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk adjustment and risk selection on the sickness fund insurance market in five European countries.
    van de Ven WP; Beck K; Buchner F; Chernichovsky D; Gardiol L; Holly A; Lamers LM; Schokkaert E; Shmueli A; Spycher S; Van de Voorde C; van Vliet RC; Wasem J; Zmora I
    Health Policy; 2003 Jul; 65(1):75-98. PubMed ID: 12818747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital merger control in Germany, the Netherlands and England: Experiences and challenges.
    Schmid A; Varkevisser M
    Health Policy; 2016 Jan; 120(1):16-25. PubMed ID: 26643437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Netherlands: health system review.
    Schäfer W; Kroneman M; Boerma W; van den Berg M; Westert G; Devillé W; van Ginneken E
    Health Syst Transit; 2010; 12(1):v-xxvii, 1-228. PubMed ID: 21132996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supplementary health insurance as a tool for risk-selection in mandatory basic health insurance markets.
    Paolucci F; Schut E; Beck K; Gress S; Van de Voorde C; Zmora I
    Health Econ Policy Law; 2007 Apr; 2(Pt 2):173-92. PubMed ID: 18634661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supervision in social health insurance: a four country study.
    Maarse H; Paulus A; Kuiper G
    Health Policy; 2005 Mar; 71(3):333-46. PubMed ID: 15694500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demand-side strategies to deal with moral hazard in public insurance for long-term care.
    Bakx P; Chernichovsky D; Paolucci F; Schokkaert E; Trottmann M; Wasem J; Schut F
    J Health Serv Res Policy; 2015 Jul; 20(3):170-6. PubMed ID: 25770020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Legal implications of the limitations of competition in healthcare systems].
    Dettling HU
    Z Evid Fortbild Qual Gesundhwes; 2009; 103(10):625-31; discussion 634. PubMed ID: 20120190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.